These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 35831856)
1. Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions. Klemencic Kozul T; Yudina A; Donovan C; Pinto A; Osman C BMC Health Serv Res; 2022 Jul; 22(1):904. PubMed ID: 35831856 [TBL] [Abstract][Full Text] [Related]
2. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Furlan JC; Barth D; Barnett C; Bril V Muscle Nerve; 2016 Jun; 53(6):872-6. PubMed ID: 26521889 [TBL] [Abstract][Full Text] [Related]
3. Safety of intravenous immunoglobulin and plasma exchange in critically ill patients. Clark SL; Rabinstein AA Neurol Res; 2015 Jul; 37(7):593-8. PubMed ID: 25751423 [TBL] [Abstract][Full Text] [Related]
4. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic. Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838 [TBL] [Abstract][Full Text] [Related]
5. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Alipour-Faz A; Shojaei M; Peyvandi H; Ramzi D; Oroei M; Ghadiri F; Peyvandi M Acta Neurol Belg; 2017 Mar; 117(1):245-249. PubMed ID: 27530310 [TBL] [Abstract][Full Text] [Related]
6. Comparison of IVIg and PLEX in patients with myasthenia gravis. Barth D; Nabavi Nouri M; Ng E; Nwe P; Bril V Neurology; 2011 Jun; 76(23):2017-23. PubMed ID: 21562253 [TBL] [Abstract][Full Text] [Related]
7. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646 [TBL] [Abstract][Full Text] [Related]
8. Safety of plasma exchange therapy in patients with myasthenia gravis. Ebadi H; Barth D; Bril V Muscle Nerve; 2013 Apr; 47(4):510-4. PubMed ID: 23322564 [TBL] [Abstract][Full Text] [Related]
9. A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Absoud M; Brex P; Ciccarelli O; Diribe O; Giovannoni G; Hellier J; Howe R; Holland R; Kelly J; McCrone P; Murphy C; Palace J; Pickles A; Pike M; Robertson N; Jacob A; Lim M Health Technol Assess; 2017 May; 21(31):1-50. PubMed ID: 28639937 [TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center. Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005 [TBL] [Abstract][Full Text] [Related]
11. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Bril V; Ilse WK; Pearce R; Dhanani A; Sutton D; Kong K Neurology; 1996 Jan; 46(1):100-3. PubMed ID: 8559353 [TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin for Guillain-Barré syndrome. Hughes RA; Swan AV; van Doorn PA Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327 [TBL] [Abstract][Full Text] [Related]
13. IVIG and PLEX in the treatment of myasthenia gravis. Bril V; Barnett-Tapia C; Barth D; Katzberg HD Ann N Y Acad Sci; 2012 Dec; 1275():1-6. PubMed ID: 23278570 [TBL] [Abstract][Full Text] [Related]
14. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. Liew WK; Powell CA; Sloan SR; Shamberger RC; Weldon CB; Darras BT; Kang PB JAMA Neurol; 2014 May; 71(5):575-80. PubMed ID: 24590389 [TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. Winters JL; Brown D; Hazard E; Chainani A; Andrzejewski C BMC Health Serv Res; 2011 May; 11():101. PubMed ID: 21575219 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Perlmutter SJ; Leitman SF; Garvey MA; Hamburger S; Feldman E; Leonard HL; Swedo SE Lancet; 1999 Oct; 354(9185):1153-8. PubMed ID: 10513708 [TBL] [Abstract][Full Text] [Related]
17. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. Heatwole C; Johnson N; Holloway R; Noyes K J Clin Neuromuscul Dis; 2011 Dec; 13(2):85-94. PubMed ID: 22361692 [TBL] [Abstract][Full Text] [Related]
18. IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. Nobile-Orazio E; Terenghi F J Neurol; 2005 May; 252 Suppl 1():I7-13. PubMed ID: 15959669 [TBL] [Abstract][Full Text] [Related]
19. Risk of thrombotic events after inpatient intravenous immunoglobulin or plasma exchange for neurologic disease: A case-crossover study. Jin PH; Shin SC; Dhamoon MS Muscle Nerve; 2020 Sep; 62(3):327-332. PubMed ID: 32270520 [TBL] [Abstract][Full Text] [Related]